



Press release

## GenSight Biologics reports its cash position as of March 31, 2017

**Paris, France, April 26, 2017, 7.30 CET** – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today reported its cash position as of March 31, 2017.

### Cash and cash equivalents

GenSight Biologics' cash and cash equivalents amounted to €48.8 million as of March 31, 2017, compared to €54.0 million as of December 31, 2016.

### Number of outstanding shares

As of March 31, 2017, GenSight Biologics' number of outstanding shares was 19,540,453 ordinary shares.

GenSight Biologics will report its financial statements and update for the first half of 2017 on July 28, 2017.

### Contacts

#### GenSight Biologics

Thomas Gidoïn

Chief Financial Officer

[tgidoïn@gensight-biologics.com](mailto:tgidoïn@gensight-biologics.com)

+33 (0)1 76 21 72 20

#### RooneyPartners

Media Relations

Marion Janic

[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)

+1-212-223-4017

#### The Trout Group

Investor Relations

Chad Rubin

[crubin@troutgroup.com](mailto:crubin@troutgroup.com)

+1-646-378-2947

### About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics' lead product candidate, GS010, is in Phase III trials in Leber's Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.